DK3658192T3 - Glucocorticoid-receptoragonist og immunokonjugater deraf - Google Patents
Glucocorticoid-receptoragonist og immunokonjugater deraf Download PDFInfo
- Publication number
- DK3658192T3 DK3658192T3 DK18833113.6T DK18833113T DK3658192T3 DK 3658192 T3 DK3658192 T3 DK 3658192T3 DK 18833113 T DK18833113 T DK 18833113T DK 3658192 T3 DK3658192 T3 DK 3658192T3
- Authority
- DK
- Denmark
- Prior art keywords
- receptoragonist
- immunoconjugates
- glucocorticoid
- glucocorticoid receptoragonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762593776P | 2017-12-01 | 2017-12-01 | |
US201762595054P | 2017-12-05 | 2017-12-05 | |
PCT/IB2018/059482 WO2019106609A1 (en) | 2017-12-01 | 2018-11-29 | Glucocorticoid receptor agonist and immunoconjugates thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3658192T3 true DK3658192T3 (da) | 2021-06-21 |
Family
ID=65010803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18833113.6T DK3658192T3 (da) | 2017-12-01 | 2018-11-29 | Glucocorticoid-receptoragonist og immunokonjugater deraf |
Country Status (34)
Country | Link |
---|---|
US (2) | US10772970B2 (da) |
EP (2) | EP3658192B1 (da) |
JP (2) | JP6813712B2 (da) |
KR (1) | KR20200095477A (da) |
CN (1) | CN111417410B (da) |
AU (1) | AU2018374634A1 (da) |
BR (1) | BR112020010694A2 (da) |
CA (1) | CA3082356A1 (da) |
CL (2) | CL2020001452A1 (da) |
CO (1) | CO2020006446A2 (da) |
CR (1) | CR20200239A (da) |
CY (1) | CY1124230T1 (da) |
DK (1) | DK3658192T3 (da) |
DO (1) | DOP2020000116A (da) |
EC (1) | ECSP20029001A (da) |
ES (1) | ES2877659T3 (da) |
HR (1) | HRP20210917T1 (da) |
HU (1) | HUE054428T2 (da) |
IL (1) | IL274651B (da) |
LT (1) | LT3658192T (da) |
MA (1) | MA49796A (da) |
MX (1) | MX2020005583A (da) |
PE (1) | PE20201286A1 (da) |
PL (1) | PL3658192T3 (da) |
PT (1) | PT3658192T (da) |
RS (1) | RS61994B1 (da) |
RU (1) | RU2020117698A (da) |
SG (1) | SG11202004867WA (da) |
SI (1) | SI3658192T1 (da) |
TW (1) | TWI803542B (da) |
UA (1) | UA126595C2 (da) |
UY (1) | UY37991A (da) |
WO (1) | WO2019106609A1 (da) |
ZA (1) | ZA202003325B (da) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI803542B (zh) * | 2017-12-01 | 2023-06-01 | 美商艾伯維有限公司 | 糖皮質激素受體激動劑及其免疫結合物 |
CA3176161A1 (en) * | 2020-04-22 | 2021-10-28 | Jay ROTHSTEIN | Anti-human vista antibodies and use thereof |
CN116761820A (zh) | 2021-02-04 | 2023-09-15 | 上海森辉医药有限公司 | 糖皮质激素受体激动剂的药物偶联物及其在医药上的应用 |
TW202304462A (zh) | 2021-03-23 | 2023-02-01 | 美商美國禮來大藥廠 | 糖皮質素受體激動劑 |
AR125079A1 (es) | 2021-03-23 | 2023-06-07 | Lilly Co Eli | Agonistas de receptores de glucocorticoides sustituidos con carboxi |
WO2022268176A1 (zh) * | 2021-06-24 | 2022-12-29 | 江苏先声药业有限公司 | 甾体类化合物、其药物组合物及其应用 |
CN117500816A (zh) * | 2021-08-26 | 2024-02-02 | 映恩生物制药(苏州)有限公司 | 一种甾体化合物及其缀合物 |
WO2023040793A1 (zh) * | 2021-09-14 | 2023-03-23 | 映恩生物制药(苏州)有限公司 | 一种抗炎症的化合物及其用途 |
TW202340252A (zh) * | 2022-01-29 | 2023-10-16 | 大陸商上海盛迪醫藥有限公司 | 糖皮質激素的藥物偶聯物 |
WO2024020164A2 (en) | 2022-07-21 | 2024-01-25 | Firefly Bio, Inc. | Glucocorticoid receptor agonists and conjugates thereof |
WO2024064779A1 (en) * | 2022-09-22 | 2024-03-28 | Eli Lilly And Company | Glucocorticoid receptor agonists |
Family Cites Families (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3126375A (en) | 1964-03-24 | Chioacyl | ||
GB933867A (en) | 1958-12-08 | 1963-08-14 | American Cyanamid Co | Fluorinated steroids |
IT1057859B (it) | 1972-04-28 | 1982-03-30 | Sigma Tao Ind Farmaceutiche Sp | Perivato del triamoinolone |
US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
EP0315456B1 (en) | 1987-11-05 | 1994-06-01 | Hybritech Incorporated | Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5010176A (en) | 1988-11-10 | 1991-04-23 | Eli Lilly And Company | Antibody-drug conjugates |
GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
WO1994022899A1 (de) | 1993-04-02 | 1994-10-13 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Neue prednisolonderivate |
WO1994025478A1 (en) | 1993-04-29 | 1994-11-10 | Instytut Farmaceutyczny | 16α,17α-ACETAL GLUCOCORTICOSTEROIDAL DERIVATIVES |
US5728826A (en) | 1994-03-09 | 1998-03-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Silyl Compounds and their use |
JP2749778B2 (ja) | 1994-09-05 | 1998-05-13 | 日清食品株式会社 | トリアムシノロン誘導体 |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
US5792758A (en) | 1995-12-08 | 1998-08-11 | G. D. Searle & Co. | Steroid nitrite ester derivatives useful as anti-inflammatory drugs |
TR199801532T2 (xx) | 1996-02-09 | 1998-11-23 | Basf Aktiengesellschaft | �nsan TNFalfa 's�n� ba�layan insan antikorlar�. |
US5824669A (en) | 1996-03-22 | 1998-10-20 | Nitromed, Inc. | Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders |
DE19635498A1 (de) | 1996-09-03 | 1998-03-26 | Byk Gulden Lomberg Chem Fab | Verfahren zur Epimerenanreicherung |
AU3703900A (en) | 1999-02-24 | 2000-09-14 | Nitromed, Inc. | Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders |
US8383081B2 (en) | 1999-05-10 | 2013-02-26 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
DE10055820C1 (de) | 2000-11-10 | 2002-07-25 | Byk Gulden Lomberg Chem Fab | Verfahren zur Herstellung eines Glucocorticoids |
CZ303885B6 (cs) | 2000-11-10 | 2013-06-12 | Takeda Gmbh | Zpusob výroby 16,17-[(cyklohexylmethylen)bis(oxy)]-11,21-dihydroxypregna-1,4-dien-3,20-dionu nebo jeho 21-isobutyrátu |
CA2385745C (en) | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
AU2002360264B2 (en) | 2001-10-10 | 2009-03-19 | Novo Nordisk A/S | Remodeling and glycoconjugation of peptides |
DE60236536D1 (de) | 2001-11-12 | 2010-07-08 | Merck Patent Gmbh | Modifizierter anti-tnf antikörper |
GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
US20040157810A1 (en) | 2002-08-23 | 2004-08-12 | Teicher Martin H. | Corticosteroid conjugates and uses thereof |
MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
CA2528776A1 (en) | 2002-10-24 | 2004-05-06 | G & R Pharmaceuticals, Llc | Antifungal formulations |
AU2003300898A1 (en) | 2002-12-13 | 2004-07-09 | Neurogen Corporation | Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators |
JP2006516636A (ja) | 2003-01-30 | 2006-07-06 | メディミューン,インコーポレーテッド | 抗インテグリンαvβ3抗体製剤及びその用途 |
MY143936A (en) | 2003-03-27 | 2011-07-29 | Nycomed Gmbh | Process for preparing crystalline ciclesonide with defined particle size |
WO2005044759A2 (en) | 2003-08-14 | 2005-05-19 | Sun Pharmaceutical Industries Limited | Acetalization process for preparation of steroid compounds |
PL1670482T5 (pl) | 2003-09-16 | 2022-10-03 | Covis Pharma Gmbh | Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego |
WO2005028495A1 (en) | 2003-09-24 | 2005-03-31 | Glaxo Group Limited | Anti-inflammatory glucocorticoids |
CA2542834C (en) | 2003-10-21 | 2012-04-24 | Igf Oncology, Llc | Conjugates or co-administration of igf-1 receptor ligands with anti-cancer chemotherapeutic agents |
SI1685131T1 (sl) | 2003-11-13 | 2007-06-30 | Hoffmann La Roche | Hidroksialkil-substituirani pirido-7-pirimidin-7-oni |
ATE360630T1 (de) | 2003-12-19 | 2007-05-15 | Bristol Myers Squibb Co | Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors |
WO2005063777A1 (en) | 2003-12-23 | 2005-07-14 | Corus Pharma | Benzylphosphate and substituted benzylphosphate prodrugs for the treatment of pulmonary inflammation |
AU2004311478A1 (en) | 2003-12-31 | 2005-07-21 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
GB0402797D0 (en) | 2004-02-09 | 2004-03-10 | Novartis Ag | Organic compounds |
US7837980B2 (en) | 2004-03-02 | 2010-11-23 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
WO2006019447A1 (en) | 2004-07-15 | 2006-02-23 | Xencor, Inc. | Optimized fc variants |
WO2006024497A1 (en) | 2004-08-30 | 2006-03-09 | Lonza Biologics Plc. | Affinity- plus ion exchange- chromatography for purifying antibodies |
ES2911482T3 (es) | 2004-09-03 | 2022-05-19 | Genentech Inc | Antagonistas anti-beta7 humanizados y usos para los mismos |
CA2579007A1 (en) | 2004-09-10 | 2006-03-16 | Altana Pharma Ag | Ciclesonide and syk inhibitor combination and methods of use thereof |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
CA2587589A1 (en) | 2004-11-29 | 2006-06-22 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
WO2006097458A1 (en) | 2005-03-15 | 2006-09-21 | Nycomed Gmbh | Novel combination |
WO2006110593A2 (en) | 2005-04-07 | 2006-10-19 | Macrogenics, Inc. | Biological targets for the diagnosis, treatment and prevention of cancer |
EP1712220A1 (en) | 2005-04-15 | 2006-10-18 | PARI GmbH Spezialisten für effektive Inhalation | Pharmaceutical aerosol composition |
WO2006135479A2 (en) | 2005-05-10 | 2006-12-21 | Angiotech International Ag | Anti-scarring agents, therapeutic compositions, and use thereof |
BRPI0611567A2 (pt) | 2005-06-14 | 2016-11-16 | Gilead Sciences Inc | composto e/ou sais farmaceuticamente aceitáveis dos mesmos, processo para síntese dos compostos, e formulação aerossol, e, uso de pelo menos uma pró-droga mútua de fenilfosfato |
PT1912677E (pt) | 2005-06-20 | 2013-12-23 | Psma Dev Company L L C | Conjugados de anticorpos contra psma-fármaco |
WO2007054974A2 (en) | 2005-09-28 | 2007-05-18 | Arch Pharmalab Limited | A green chemistry process for the preparation of pregnadiene esters |
EP2004231A4 (en) | 2006-04-07 | 2013-07-10 | Nektar Therapeutics | CONJUGATES OF ANTI-TNF-ALPHA ANTIBODY |
WO2008015696A2 (en) | 2006-05-23 | 2008-02-07 | Cadila Healthcare Limited | Process for preparing ciclesonide |
RS54163B1 (en) | 2006-05-30 | 2015-12-31 | Genentech Inc. | ANTI-CD22 ANTIBODIES, THEIR IMMUNCONJUGATES AND THEIR USE |
US8158780B2 (en) | 2006-09-19 | 2012-04-17 | Cipla Limited | Processes for the preparation of ciclesonide and its crystal modification |
WO2008052350A1 (en) | 2006-11-03 | 2008-05-08 | Qlt Inc. | Photodynamic therapy for the treatment of hidradenitis suppurativa |
NO331891B1 (no) | 2007-03-20 | 2012-04-30 | Clavis Pharma Asa | Kjemiske forbindelser, et farmasoytisk preparat inneholdende slike forbindelser, samt anvendelse derav for behandling av kreft, inflammasjon og KOLS |
UA100120C2 (en) | 2007-04-03 | 2012-11-26 | Анадис Фармасьютикалз, Инк. | 5,6-dihydro-1h-pyridin-2-one compounds |
CN101795565A (zh) | 2007-06-28 | 2010-08-04 | 锡德克斯药物公司 | 皮质类固醇水溶液的鼻部和眼部给药 |
NZ585434A (en) * | 2007-11-30 | 2012-06-29 | Pfizer Ltd | Novel glucocorticoid receptor agonists |
US8524697B2 (en) | 2007-12-21 | 2013-09-03 | Merck Sharp & Dohme Corp. | C20-C21 substituted glucocorticoid receptor agonists |
WO2009085880A2 (en) | 2007-12-21 | 2009-07-09 | Schering Corporation | C-21 thioethers as glucocorticoid receptor agonists |
PT2238170T (pt) | 2008-01-31 | 2017-02-21 | Inserm - Inst Nat De La Santé Et De La Rech Médicale | Anticorpos contra cd39 humano e seu uso para inibição da actividade de células t reguladoras |
BRPI0907789A2 (pt) | 2008-02-27 | 2019-01-22 | Astrazeneca Ab | derivaldos 16-alfa e 17-alfa de glicocorticosteroides e seus usos |
EP2262823B1 (en) | 2008-03-13 | 2013-01-23 | Farmabios S.p.A. | Process for the preparation of pregnane derivatives |
TW201010707A (en) | 2008-06-10 | 2010-03-16 | Gilead Sciences Inc | Corticosteroid linked beta-agonist compounds for use in therapy |
JP2011524421A (ja) | 2008-06-16 | 2011-09-01 | イミュノジェン・インコーポレーテッド | 新規の相乗効果 |
CA2729212C (en) | 2008-06-24 | 2014-04-01 | Irm Llc | Compounds and methods for modulating g protein-coupled receptors |
WO2010054158A2 (en) | 2008-11-07 | 2010-05-14 | Auspex Pharmaceuticals, Inc. | Steroid modulators of glucocorticoid receptor |
SG171812A1 (en) | 2008-12-04 | 2011-07-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
KR101940059B1 (ko) | 2008-12-19 | 2019-01-18 | 마크로제닉스, 인크. | 공유결합형 디아바디 및 이의 용도 |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
CA2754589C (en) | 2009-03-09 | 2013-07-16 | Mikasa Seiyaku Co., Ltd. | Steroid compound |
WO2010126953A1 (en) | 2009-04-29 | 2010-11-04 | Gilead Sciences, Inc. | Corticosteroid linked beta-agonist compounds for use in therapy |
WO2010132743A1 (en) | 2009-05-15 | 2010-11-18 | Gilead Sciences, Inc. | Corticosteroid beta-agonist compounds for use in therapy |
WO2010136940A1 (en) | 2009-05-29 | 2010-12-02 | Pfizer Limited | Novel glucocorticoid receptor agonists |
GB0917044D0 (en) | 2009-09-29 | 2009-11-18 | Cytoguide As | Agents, uses and methods |
RU2580038C2 (ru) | 2009-12-04 | 2016-04-10 | Дженентек, Инк. | Мультиспецифические антитела, аналоги антител, композиции и способы |
CA2782398C (en) | 2009-12-09 | 2017-09-26 | Immunomedics, Inc. | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
WO2011081937A1 (en) | 2009-12-15 | 2011-07-07 | Gilead Sciences, Inc. | Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy |
CN102167741B (zh) | 2010-02-25 | 2014-05-14 | 上海百迈博制药有限公司 | 一种全人源抗TNF-α单克隆抗体、其制备方法及用途 |
BR112012025568A2 (pt) | 2010-04-07 | 2017-03-28 | Abbvie Inc | proteínas de ligação ao tnf-<244>. |
MX346731B (es) | 2010-04-23 | 2017-03-30 | Genentech Inc * | Producción de proteínas heteromultiméricas. |
CA2799202C (en) | 2010-05-18 | 2016-07-05 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
WO2011153477A2 (en) | 2010-06-03 | 2011-12-08 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of hidradenitis suppurativa (hs) |
BR112012032778A2 (pt) | 2010-06-24 | 2019-09-24 | Abbvie Inc | "proteínas multiespecíficas e multivalentes" |
AU2011305566A1 (en) | 2010-09-22 | 2013-05-02 | Map Pharmaceuticals, Inc. | Aerosol composition for administering drugs |
AR084210A1 (es) | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
WO2012082947A1 (en) | 2010-12-16 | 2012-06-21 | Irm Llc | Compounds and compositions as tgr5 agonists |
WO2012089247A1 (en) | 2010-12-29 | 2012-07-05 | Nokia Siemens Networks Oy | A method and apparatus for transmitting an identity |
KR20140018299A (ko) | 2011-03-30 | 2014-02-12 | 아블린쓰 엔.브이. | Tnf-알파에 대한 단일 도메인 항체를 이용하여 면역 장애를 치료하는 방법 |
PE20142245A1 (es) | 2011-10-24 | 2015-01-22 | Abbvie Inc | Inmunoligantes biespecificos dirigidos contra tnf e il-17 |
KR20140084253A (ko) | 2011-10-24 | 2014-07-04 | 애브비 인코포레이티드 | Tnf에 대한 면역결합제 |
US20130115269A1 (en) | 2011-11-04 | 2013-05-09 | Henry John Smith | Anti-tumor necrosis factor alpha (TNF-a) antibody used as a targeting agent to treat arthritis and other diseases |
WO2013087914A1 (en) | 2011-12-16 | 2013-06-20 | Synthon Biopharmaceuticals B.V. | EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED |
US9109005B2 (en) | 2012-02-23 | 2015-08-18 | Boehringer Ingelheim International Gmbh | Method for manufacturing of ciclesonide |
EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
EP2647627A1 (en) | 2012-04-02 | 2013-10-09 | Almirall, S.A. | Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one. |
CN103421075B (zh) | 2012-05-16 | 2017-07-28 | 上海特化医药科技有限公司 | 孕烷衍生物16,17‑缩醛(酮)的制备方法 |
WO2013181585A2 (en) | 2012-06-01 | 2013-12-05 | Momenta Pharmaceuticals, Inc. | Methods related to adalimumab |
CN104854133B (zh) | 2012-10-12 | 2018-10-30 | 新加坡科技研究局 | 用于制备重组抗体治疗剂的最佳重链和轻链信号肽 |
AU2012395148B2 (en) | 2012-11-24 | 2016-10-27 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
WO2015012904A2 (en) | 2012-12-13 | 2015-01-29 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
MX364652B (es) | 2012-12-21 | 2019-05-03 | Boehringer Ingelheim Vetmedica Gmbh | Formulacion farmaceutica que comprende ciclesonida. |
CN105189550A (zh) | 2013-03-15 | 2015-12-23 | 艾伯维公司 | 改善的tnf结合蛋白 |
CA2920192A1 (en) | 2013-09-27 | 2015-04-02 | Immunomedics, Inc. | Anti-trop-2 antibody-drug conjugates and uses thereof |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
EP3122757B1 (en) | 2014-02-28 | 2023-09-06 | Hangzhou Dac Biotech Co., Ltd | Charged linkers and their uses for conjugation |
WO2015153401A1 (en) * | 2014-04-04 | 2015-10-08 | Merck Sharp & Dohme Corp | Phosphate based linkers for intracellular delivery of drug conjugates |
CA2948013A1 (en) | 2014-06-30 | 2016-01-07 | Immunomedics, Inc. | Antibodies reactive with an epitope located in the n-terminal region of muc5ac comprising cysteine-rich subdomain 2 (cys2) |
US20180250224A1 (en) | 2014-09-19 | 2018-09-06 | Oxular Limited | Ophthalmic Drug Compositions |
WO2016120891A1 (en) | 2015-01-30 | 2016-08-04 | Coral Drugs Pvt. Ltd. | Novel process for preparation of glucocorticoid steroids |
JP2016190798A (ja) | 2015-03-31 | 2016-11-10 | 三笠製薬株式会社 | アレルギー性鼻炎治療用局所点鼻薬 |
NZ737471A (en) | 2015-06-15 | 2022-02-25 | Hangzhou Dac Biotech Co Ltd | Hydrophilic linkers for conjugation |
CN116726190A (zh) | 2015-06-20 | 2023-09-12 | 杭州多禧生物科技有限公司 | 澳瑞他汀类似物及其与细胞结合分子的共轭偶联物 |
JP6817288B2 (ja) | 2015-08-10 | 2021-01-20 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. | 新規な連結体及び生体分子と薬物との特異的共役におけるその使用 |
JP2017066075A (ja) | 2015-09-30 | 2017-04-06 | 三笠製薬株式会社 | リウマチ治療薬 |
MY194619A (en) | 2016-06-02 | 2022-12-07 | Abbvie Inc | Glucocorticoid receptor agonist and immunoconjugates thereof |
JP6767796B2 (ja) | 2016-07-08 | 2020-10-14 | 株式会社日立情報通信エンジニアリング | 通話管理システム及びその音声認識制御方法 |
SG10202104259RA (en) | 2016-11-08 | 2021-06-29 | Regeneron Pharma | Steroids and protein-conjugates thereof |
TWI803542B (zh) * | 2017-12-01 | 2023-06-01 | 美商艾伯維有限公司 | 糖皮質激素受體激動劑及其免疫結合物 |
-
2018
- 2018-11-29 TW TW107142830A patent/TWI803542B/zh active
- 2018-11-29 RU RU2020117698A patent/RU2020117698A/ru unknown
- 2018-11-29 EP EP18833113.6A patent/EP3658192B1/en active Active
- 2018-11-29 MX MX2020005583A patent/MX2020005583A/es unknown
- 2018-11-29 WO PCT/IB2018/059482 patent/WO2019106609A1/en unknown
- 2018-11-29 UA UAA202003245A patent/UA126595C2/uk unknown
- 2018-11-29 CN CN201880077432.9A patent/CN111417410B/zh active Active
- 2018-11-29 PT PT188331136T patent/PT3658192T/pt unknown
- 2018-11-29 ES ES18833113T patent/ES2877659T3/es active Active
- 2018-11-29 MA MA049796A patent/MA49796A/fr unknown
- 2018-11-29 AU AU2018374634A patent/AU2018374634A1/en active Pending
- 2018-11-29 SG SG11202004867WA patent/SG11202004867WA/en unknown
- 2018-11-29 CR CR20200239A patent/CR20200239A/es unknown
- 2018-11-29 PE PE2020000608A patent/PE20201286A1/es unknown
- 2018-11-29 BR BR112020010694-1A patent/BR112020010694A2/pt unknown
- 2018-11-29 PL PL18833113T patent/PL3658192T3/pl unknown
- 2018-11-29 EP EP21162680.9A patent/EP3884962A1/en active Pending
- 2018-11-29 LT LTEP18833113.6T patent/LT3658192T/lt unknown
- 2018-11-29 CA CA3082356A patent/CA3082356A1/en active Pending
- 2018-11-29 JP JP2020512845A patent/JP6813712B2/ja active Active
- 2018-11-29 HU HUE18833113A patent/HUE054428T2/hu unknown
- 2018-11-29 RS RS20210761A patent/RS61994B1/sr unknown
- 2018-11-29 DK DK18833113.6T patent/DK3658192T3/da active
- 2018-11-29 KR KR1020207015633A patent/KR20200095477A/ko active Search and Examination
- 2018-11-29 SI SI201830305T patent/SI3658192T1/sl unknown
- 2018-11-29 US US16/204,825 patent/US10772970B2/en active Active
- 2018-12-03 UY UY0001037991A patent/UY37991A/es not_active Application Discontinuation
-
2020
- 2020-05-13 IL IL274651A patent/IL274651B/en active IP Right Grant
- 2020-05-27 CO CONC2020/0006446A patent/CO2020006446A2/es unknown
- 2020-05-29 EC ECSENADI202029001A patent/ECSP20029001A/es unknown
- 2020-05-29 CL CL2020001452A patent/CL2020001452A1/es unknown
- 2020-06-03 ZA ZA2020/03325A patent/ZA202003325B/en unknown
- 2020-06-15 DO DO2020000116A patent/DOP2020000116A/es unknown
- 2020-07-31 US US16/945,069 patent/US20210015938A1/en not_active Abandoned
- 2020-12-17 JP JP2020209056A patent/JP2021054845A/ja active Pending
-
2021
- 2021-04-26 CL CL2021001075A patent/CL2021001075A1/es unknown
- 2021-06-09 HR HRP20210917TT patent/HRP20210917T1/hr unknown
- 2021-06-18 CY CY20211100547T patent/CY1124230T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3658192T3 (da) | Glucocorticoid-receptoragonist og immunokonjugater deraf | |
DK3383916T3 (da) | Anti-CD73-antistoffer og anvendelser deraf | |
DK3610005T3 (da) | Peptidligase og anvendelse deraf | |
DK3448386T3 (da) | Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf | |
DK3458479T3 (da) | Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater | |
DK3443009T3 (da) | Anti-tim-3-antistoffer og sammensætninger | |
DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
DK3607069T3 (da) | Produkter og sammensætninger | |
DK3365368T3 (da) | Tgfbeta1-bindende immunoglobuliner og anvendelse deraf | |
DK3264955T3 (da) | Blandeanordning og fremgangsmåde | |
DK3191135T3 (da) | Anti-HER2-antistoffer og immunokonjugater | |
DK3504242T3 (da) | Anti-ox40-antistoffer og anvendelse deraf | |
DK3411034T3 (da) | Selektiv østrogenreceptornedbrydere og anvendelser deraf | |
DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
DK3536698T3 (da) | Lanosterol-prodrugforbindelse og anvendelse deraf | |
DK3668512T3 (da) | Pyruvatkinasemodulatorer og anvendelse deraf | |
DK3532499T3 (da) | ANTI-IL-33-antistoffer og anvendelser deraf | |
DK3640207T3 (da) | Molekularsi scm-15, syntesefremgangsmåde dertil og anvendelse deraf | |
DK3402821T3 (da) | Psma-bindende antistof og anvendelser deraf | |
DK3287810T3 (da) | Vindmålingsindretning og lidarindretning | |
DK3265641T3 (da) | Stigørenhed og fremgangsmåde | |
DK3612579T3 (da) | Pultrudat, fremstilling og anvendelse heraf | |
DK3621694T3 (da) | Lrrc33-inhibitorer og anvendelse heraf | |
DK3692009T3 (da) | Biocementationsfremgangsmåde og system | |
MA49905A (fr) | Polyesteramines et polyesterquats |